Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

HXR9

😃Good
Catalog No. T41062Cas No. 917953-08-3

HXR9 is a cell-permeable peptide that acts as a competitive antagonist of the HOX/PBX interaction, effectively inhibiting the binding between HOX proteins and the transcription factor PBX in paralogue groups 1 to 8. HXR9 selectively impairs cell proliferation and induces apoptosis in cells with high expression of the HOXA/PBX3 genes (e.g., MLL-rearranged leukemic cells).

HXR9

HXR9

😃Good
Catalog No. T41062Cas No. 917953-08-3
HXR9 is a cell-permeable peptide that acts as a competitive antagonist of the HOX/PBX interaction, effectively inhibiting the binding between HOX proteins and the transcription factor PBX in paralogue groups 1 to 8. HXR9 selectively impairs cell proliferation and induces apoptosis in cells with high expression of the HOXA/PBX3 genes (e.g., MLL-rearranged leukemic cells).
Pack SizePriceAvailabilityQuantity
25 mg1.444 €Backorder
Bulk & Custom
Add to Cart
Questions
View More
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
HXR9 is a cell-permeable peptide that acts as a competitive antagonist of the HOX/PBX interaction, effectively inhibiting the binding between HOX proteins and the transcription factor PBX in paralogue groups 1 to 8. HXR9 selectively impairs cell proliferation and induces apoptosis in cells with high expression of the HOXA/PBX3 genes (e.g., MLL-rearranged leukemic cells).
In vitro
HXR9 at a concentration of 60μM effectively disrupts the interaction between PBX and HOX within 4 hours, and at the same duration, it also blocks the binding of HOXD9 to PBX in murine B16 melanoma cells as confirmed by Western Blot Analysis. Additionally, a 2-hour treatment with HXR9 induces apoptosis in B16 and primary melanoma cells, with a significant increase in late apoptosis phases observed in B16 cells. This compound also prompts specific transcriptional alterations, notably the upregulation of Fos, Jun, Dusp1, and Atf1 as demonstrated by RT-PCR in B16F10 cells. Moreover, HXR9 exhibits antiproliferative effects on B16 cells, with an IC50 value of 20μM, highlighting its potential as a therapeutic agent in melanoma treatment.
In vivo
HXR9, administered intravenously (i.v.) via the tail vein at a dosage of 10 mg/kg twice weekly, effectively inhibits tumor growth, as evidenced in C57black/6 mice bearing B16 cells, leading to significant retardation of tumor progression over approximately 30 days. Similarly, when commenced with an initial dose of 100 mg/kg followed by a maintenance dosing of 10 mg/kg twice weekly via intraperitoneal injection for 18 days, HXR9 substantially suppresses A549 tumor growth in vivo in athymic nude mice, resulting in markedly smaller tumors compared to those in control groups. This consistent anti-tumor activity of HXR9 underscores its potential in treating different tumor types across various animal models.
Chemical Properties
Molecular Weight2718.26
FormulaC119H193N53O20S
Cas No.917953-08-3
Storage & Solubility Information
Storagekeep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy HXR9 | purchase HXR9 | HXR9 cost | order HXR9 | HXR9 chemical structure | HXR9 in vivo | HXR9 in vitro | HXR9 formula | HXR9 molecular weight